- About
- Training
- Required Training
- Research Specific Training
- Biosafety and Biosecurity
- Use of Controlled Substances in Basic and Animal Research
- Clinical Research Coordinator
- Clinical Trial Billing Compliance
- ClinicalTrials.gov
- Environmental Health & Safety (EHS)
- Export Controls
- Good Clinical Practice (GCP)
- Good Laboratory Practice
- Humanitarian Use Device (HUD)
- Human Stem Cell Oversight
- International Research
- Privacy & Information Security for Researchers
- Radiation Safety
- Research with Children
- Training Table
- Collaborative Institutional Training Initiative (CITI)
- Video Presentations Library
- Resources
- Events
- NEWS
- People
- Contact
- Report a Concern
Test-Checklist
Investigators leaving the University should consult with the relevant administrator(s) for their school and department to plan the relocation. Contact the Office of Sponsored Programs if you need assistance in identifying these individuals.
Investigators departing the University must complete this online form as far in advance as possible. Completion of this form will alert the relevant University offices, which will be in contact to assure that your research at the University is terminated appropriately. In addition to completing this form, the departing investigator must also notify their primary department administrator well in advance of their departure.
Additional guidelines are below and as well as a checklist for investigators leaving the University.
Download checklist (PDF)
General Procedures for Closing Laboratories
Multiple steps are involved in ensuring that laboratories are properly closed.
DEA Controlled Substances
There is protocol for properly disposing of DEA-controlled substances. Abandoning them is a violation of federal law.
Radiation-Producing Devices and Materials
Radiation-labeled work areas or equipments, including radiation-emitting equipment, must be handled according to protocol.
Studies Using Animal Subjects
Specific guidelines for terminating IACUC protocals are detailed and crucial.
Studies Using Recombinant DNA
All protocols approved by the Institutional Biosafety Committee (IBC) for which the departing investigator is designated as the PI must be terminated, or an alternate PI should be designated via a protocol modification form. Further details are available through the IBC Office. Contact them via email or phone at 412-383-1768.
Studies Using Human Subjects
Principal investigators leaving the institution are responsible for making appropriate arrangements well in advance of their departure.
Studies Conducted Under a University-based, Sponsor-Investigator Investigational New Drug (IND) or Investigational Device Exemption (IDE) Application
Studies Approved by the hSCRO
All Human Stem Cell Research Oversight Committee (hSCRO)-approved protocols, including protocols that do not require Committee approval, for which the departing investigator is designated the PI must be terminated, or an alternate PI should be designated via a protocol modification form. Contact the hSCRO Office for further details.
Fiscal Matters
Specific steps must be taken to with regard to fiscal matters, but they can vary.
Intellectual Property and Rights in Data
Guidelines for intellectual property and rights are multifaceted and are crucial to know.
Studies Registered on ClinicalTrial.gov
If the departing individual is the Sponsor or Investigator of a study registered in the University of Pittsburgh PRS account, the Sponsor, Responsible Party or Sponsor Organization may need to be changed. Contact the University of Pittsburgh Office for ClinicalTrials.gov at ctgov@pitt.edu well in advance of departure to discuss options and required changes.